FOXM1 and cancer: Recently, we have obtained a new cell-penetrating protein reagent, M1-138, which is a recombinant FOXM1 N-terminal domain (1-138aa) fused with a nine arginine cell-penetrating peptide, to reduce the proliferation and migration abilities of cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3 [28].